Starling Oncology, Inc. (STLN) insider trading.
In Q3 2026, insiders at Starling Oncology, Inc. reported 17 non-derivative transactions on 14 Forms 3, 4 and 5: 3 open-market purchases worth $261K and 3 sales worth $2.1M.
- Transactions
- 17
- Purchases (P)
- 3
- Sales (S)
- 3
- Net shares, P minus S
- -277,305
- Insiders
- 9
- Last filed
- 2026-08-24
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Podnos Yale | Officer · Chief Medical Officer | 4 | 0 | 2 |
| Chernett Jorey | TenPercentOwner | 3 | 3 | 0 |
| Hively Brad | Director | 2 | 0 | 1 |
| Tzoumakas Kimberly Jo | Director | 2 | 0 | 0 |
| Stolper Mark | Director | 2 | 0 | 0 |
| Johnson Karen Marie | Director | 1 | 0 | 0 |
| Pacala Mark L | Director | 1 | 0 | 0 |
| McGeorge Anne | Director | 1 | 0 | 0 |
| Kaushal Mohit | Director | 1 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-21 | Hively Brad | S (D) | 298,853 | $6.51 | 411,976 | Form 4 |
| 2026-08-14 | Chernett Jorey | P (A) | 12,000 | $6.54 | 10,660,858 | Form 4 |
| 2026-07-27 | Johnson Karen Marie | A (A) | 31,124 | $0 | 319,410 | Form 4 |
| 2026-07-27 | Hively Brad | A (A) | 27,108 | $0 | 710,829 | Form 4 |
| 2026-07-27 | Tzoumakas Kimberly Jo | A (A) | 29,116 | $0 | 46,301 | Form 4 |
| 2026-07-27 | Stolper Mark | A (A) | 31,124 | $0 | 56,957 | Form 4 |
| 2026-07-27 | Pacala Mark L | A (A) | 30,120 | $0 | 286,881 | Form 4 |
| 2026-07-27 | McGeorge Anne | A (A) | 41,165 | $0 | 332,535 | Form 4 |
| 2026-07-27 | Kaushal Mohit | A (A) | 33,133 | $0 | 205,716 | Form 4 |
| 2026-07-21 | Chernett Jorey | P (A) | 18,000 | $5.27 | 10,648,858 | Form 4 |
| 2026-07-14 | Podnos Yale | M (A) | 5,478 | $2 | 265,005 | Form 4 |
| 2026-07-14 | Podnos Yale | S (D) | 5,478 | $6.35 | 259,527 | Form 4 |
| 2026-07-14 | Podnos Yale | S (D) | 17,974 | $6.43 | 259,527 | Form 4 |
| 2026-07-14 | Podnos Yale | M (A) | 17,974 | $1.87 | 277,501 | Form 4 |
| 2026-07-10 | Chernett Jorey | P (A) | 15,000 | $5.85 | 10,630,858 | Form 4 |
| 2026-07-07 | Stolper Mark | A (A) | 25,833 | $0 | 25,833 | Form 4 |
| 2026-07-07 | Tzoumakas Kimberly Jo | A (A) | 17,185 | $0 | 17,185 | Form 4 |
Transaction codes in this quarter
Get STLN insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1799191&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · STLN company page · Starling Oncology, Inc. on SEC.gov
Questions
Are insiders buying or selling Starling Oncology, Inc. (STLN)?
In Q3 2026, insiders at Starling Oncology, Inc. reported 17 non-derivative transactions on 14 Forms 3, 4 and 5: 3 open-market purchases worth $261K and 3 sales worth $2.1M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Starling Oncology, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/stln.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.